Valencia, California-based SetPoint Medical Corp. announced today it will enroll 15 rheumatoid arthritis (RA) patients in a study to assess the safety and effectiveness of its unique vagus nerve stimulation system. Patients must be ages 22-75 and have failed to adequately respond to multiple biologic agents.
The pilot trial builds on SetPoint's previously published results from a proof-of-concept study of 17 patients with active RA. In...